PARP inhibitors for maintenance therapy in ovarian cancer will be the No. 9 most influential medical innovation for 2020, predict experts at Cleveland Clinic.
Many patients with ovarian cancer receive aggressive care at the end of their lives. Gynecologic oncologist, Chad Michener, MD, presents preliminary data from research into barriers to timely palliative and hospice care referrals, as perceived by physicians.
HIPEC improves survival, though careful intraoperative management is key. Robert DeBernardo, MD, explains the results of a HIPEC study presented at the Society for Gynecologic Oncology’s Annual Meeting.
A group of Ob-Gyns recently analyzed clinical prognostic factors for survival after recurrence of high-grade, advanced-stage ovarian cancer.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
With his new, five-year, $1.8 million award, Dr. Gong hopes to improve PARPi therapy by better understanding the mechanisms of resistance.
A retrospective review found that the presence of variants of uncertain significance on multigene panel testing does not increase the rate of contralateral prophylactic mastectomies.
The data are promising regarding PARP inhibitors, especially in recurrent ovarian cancer. Gynecologic oncologists are awaiting results of current trials in patients with newly diagnosed ovarian cancer as part of primary therapy.